BMY vs JNJ: Healthcare Revenue Comparison for 2025
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowIn fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb is a major pharmaceutical company focused on oncology and immunology.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BMY news
- BMY and JNJ Financials: 2025 Revenue Numbers Declared
- SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
- Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
- Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
- Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
